Xenon Pharmaceuticals Inc. (XENE) is in Healthcare, Biotechnology, based in Canada, listed on NasdaqGM. Market cap 3.50B USD. 52-week range 35.06 to 72.66 USD. Data as of 2026-10-09.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as ...